Table 4.
Most-Altered Canonical Pathways 1 | Ratio 2 | p Value 3 |
---|---|---|
Citrinin | ||
Superpathway of cholesterol biosynthesis | 17/23 (0.739) | *** |
Cholesterol biosynthesis I | 8/10 (0.80) | *** |
Cholesterol biosynthesis II (via 24, 25-dihydrolanosterol) | 8/10 (0.80) | *** |
Cholesterol biosynthesis III (via desmosterol) | 8/10 (0.80) | *** |
tRNA charging | 16/32 (0.5) | *** |
Ochratoxin A | ||
P2Y purigenic receptor signaling pathway | 43/93 | ** |
Breast cancer regulation by Stathmin1 | 58/137 | ** |
PPAR signaling | 33/69 (0.478) | ** |
CREB signaling in neurons | 50/117 (0.427) | ** |
GADD45 Signaling | 11/17 (0.647) | ** |
Citrinin + Ochratoxin A | ||
EIF2 signaling | 85/182 (0.443) | *** |
Regulation of eIF4 and p70S6K signaling | 57/146 (0.39) | *** |
Molecular mechanisms of cancer | 114/365 (0.312) | *** |
mTOR signaling | 67/188 (0.356) | *** |
Germ cell-Sertoli cell junction signaling | 56/160 (0.35) | *** |
1 Differentially expressed genes in CIT, OTA and CIT + OTA groups at 6 h after PM exposure underwent Core analysis, which interprets the data set in the context of biological processes, pathways and molecular networks (Ingenuity® Systems); 2 (Differentially expressed genes)/(Total number of genes on the pathway); 3 A p-value associated with a pathway was calculated using Fisher’s exact test to determine the probability that the association between affected genes and a canonical pathway is explained by chance alone; * denotes significance at p < 0.05; ** denotes significance at p < 0.01; *** denotes significance at p < 0.01.